Mylan appoints two heads to Board of directors
pharmafile | February 12, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Mylan
Mylan has announced the appointment of Melina Higgins, a former partner at Goldman Sachs, and Rajiv Malik, currently Mylan’s president, to its Board.
Higgins is an experienced financier, having served as a partner and in other senior roles at Goldman Sachs during her nearly 20-year career at the firm. Higgins joined Goldman Sachs in 1989 and retired from the company in January 2010.
Higgins said: “I believe Mylan is truly differentiated within the industry and very well-positioned to continue to generate value for its shareholders by executing on its strategy. I am very excited to be joining Mylan’s board and look forward to working alongside my fellow directors and Mylan’s highly talented management team during this period of continued anticipated growth and strategic evolution for the company.”
Malik (pictured) is currently Mylan’s president, responsible for the company’s operations, including oversight for research and development, business development, regulatory affairs, manufacturing operations and strategy, quality, supply chain, sourcing, packaging and medical affairs, as well as the sales and marketing of Mylan’s generics business.
Malik has approximately 30 years of experience in the global generic pharmaceutical industry. Prior to joining Matrix in 2005, Malik was head of Global Development and Regulatory at Sandoz. He started his R&D career at Ranbaxy Laboratories, rising to head of Generics R&D.
He said: “I feel privileged and honored to be elevated to the Mylan board. Since joining Mylan following the acquisition of Matrix, I have felt like a part of the Mylan family, a feeling shared by many others who have joined me on this exciting journey over the past few years.”
Mylan executive chairman Robert Coury added: “With these appointments, I am very pleased to continue to deliver on our objective of enhancing and strengthening Mylan at all levels, including its board of directors, as we seek to continue our exciting growth trajectory.”
Related Content
Pfizer to pay $345 million in EpiPen lawsuit
Pfizer has reached a $345 million settlement over consumer claims they overpaid for EpiPens as …
Mylan reaches agreement with Aspen for their European thrombosis business
Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s …
Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute
The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding …
